Europe Regenerative Agriculture Practices Analysis and Forecast Report 2024-2025 & 2034: Opportunities in the Expansion of Carbon Markets - Focus on Germany, France, UK, Italy
DUBLIN--(BUSINESS WIRE)--May 27, 2025--
The 'Europe Regenerative Agriculture Practices Market: Focus on Application, Types of Practice, and Country - Analysis and Forecast, 2024-2034" report has been added to ResearchAndMarkets.com's offering.
The Europe regenerative agriculture practices market, valued at $4.08 billion in 2024, is expected to reach $13.27 billion by 2034, exhibiting a robust CAGR of 12.51% during the forecast period 2024-2034
The growth of the regenerative agriculture market in Europe is driven by a strong focus on sustainability and soil health restoration. Government policies and initiatives supporting eco-friendly farming, along with increasing consumer demand for organic and sustainably sourced products, are key factors. Additionally, technological advancements and data-driven solutions enhance the efficient adoption of regenerative farming practices.
Market Overview
The growing emphasis on sustainability, soil health restoration, and climate resilience is propelling the market for regenerative agriculture practices in Europe. Initiatives like the Common Agricultural Policy (CAP) and the Farm to Fork Strategy encourage regenerative practices to increase biodiversity, improve soil fertility, and lower carbon emissions as the European Union (EU) strengthens its commitment to environmentally friendly farming.
Another significant factor driving market expansion is consumer demand for food that is sourced sustainably and organically. Regenerative supply chains that support sustainability objectives are becoming more and more important to consumers and businesses as they become more conscious of the environmental effects of conventional farming.
The use of regenerative agriculture is also being accelerated by technological developments such as data-driven decision-making, AI-driven soil monitoring, and precision farming. Farmers can increase yield and profitability while optimising resource use thanks to these innovations.
Carbon sequestration methods, crop rotation, agroforestry, cover crops, and no-till farming are important regenerative practices that are becoming more popular in Europe. The market for regenerative agriculture practices in Europe is expected to grow further due to rising investments, government incentives, and corporate commitments to sustainable sourcing. This will help to shape the future of environmentally conscious and sustainable food production.
How can this report add value to an organization?
Practice/Innovation Strategy: The practice segment helps the reader understand the specific techniques and methodologies employed in regenerative agriculture, such as soil health management, water management, and biodiversity enhancement. It also provides insight into how these practices contribute to creating sustainable and resilient agricultural systems. Additionally, the study offers a detailed overview of the current state of various regenerative agriculture projects developed by companies and non-profit organizations.
Growth/Marketing Strategy: The Europe regenerative agriculture practices market has seen major development by key participants operating in the market, such as business expansion, partnership, collaboration, and joint venture. The favored strategies of the companies have been partnership, collaboration, and joint venture activities to strengthen their position in the Europe regenerative agriculture practices market.
Competitive Strategy: Key players in the Europe regenerative agriculture practices market analyzed and profiled in the study include project developers and accounting tool providers. The analysis covers market segments by distinct practices, applications served, regional presence, and the impact of key market strategies. Additionally, detailed competitive benchmarking has been conducted to illustrate how players compare, providing a clear view of the market landscape. The study also examines comprehensive competitive strategies, such as partnerships, agreements, and collaborations, to help identify untapped revenue opportunities in the regenerative agriculture practices market.
Key Market Players
Key Attributes:
Key Topics Covered:
Executive Summary
Scope and Definition
1 Market: Industry Outlook
1.1 Trends: Current and Future Impact Assessment
1.1.1 Increasing Consumer Demand for Organic Foods
1.1.2 Rising Carbon Credit Prices
1.2 Research and Development Review
1.2.1 Patent Filing Trend (by Country and Company)
1.3 Stakeholder Analysis
1.4 Market Dynamics Overview
1.4.1 Market Drivers
1.4.1.1 Increasing Corporate Sustainability Goals
1.4.1.2 Rising Soil Health Degradation
1.4.2 Market Challenges
1.4.2.1 High Upfront Costs for Farmers
1.4.2.2 Lack of Standardized Measurement and Certification
1.4.3 Market Opportunities
1.4.3.1 Technological Advancements in Monitoring and Data Analytics
1.4.3.2 Expansion of Carbon Markets
1.5 Startup Funding Summary
1.6 State of Regenerative Agriculture Practice Adoption
1.6.1 Agri-food Companies Commitment to Regenerative Agriculture Factors
1.6.2 Regenerative Agriculture Program and their Acreage Coverage Data
1.6.3 Project Developers Acreage Coverage
1.6.4 Case Study
2 Region
2.1 Regional Summary
2.2 Europe
2.2.1 Regional Overview
2.2.2 Driving Factors for Market Growth
2.2.3 Factors Challenging the Market
2.2.3.1 Application
2.2.3.2 Practice
2.2.4 Germany
2.2.4.1 Application
2.2.4.2 Practice
2.2.5 France
2.2.5.1 Application
2.2.5.2 Practice
2.2.6 U.K.
2.2.6.1 Application
2.2.6.2 Practice
2.2.7 Italy
2.2.7.1 Application
2.2.7.2 Practice
2.2.8 Rest-of-Europe
2.2.8.1 Application
2.2.8.2 Practice
3 Markets - Competitive Benchmarking & Company Profiles
3.1 Geographic Assessment
3.2 Company Profiles
3.3 Project Developers
3.3.1 reNature
3.3.1.1 Overview
3.3.1.2 Top Projects/Initiatives
3.3.1.3 Target Customers
3.3.1.4 Key Personnel
3.3.1.5 Analyst View
3.3.2 South Pole
3.3.2.1 Overview
3.3.2.2 Top Projects/Initiatives
3.3.2.3 Target Customers
3.3.2.4 Key Personnel
3.3.2.5 Analyst View
3.4 Accounting Tool Providers
3.4.1 Soil Capital Ltd.
3.4.1.1 Overview
3.4.1.2 Top Programs/Program Portfolio
3.4.1.3 Top Competitors
3.4.1.4 Target Customers
3.4.1.5 Key Personnel
3.4.1.6 Analyst View
3.4.2 Agreena
3.4.2.1 Overview
3.4.2.2 Top Products/Product Portfolio
3.4.2.3 Top Competitors
3.4.2.4 Target Customers
3.4.2.5 Key Personnel
3.4.2.6 Analyst View
4 Research Methodology
For more information about this report visit https://www.researchandmarkets.com/r/13vadz
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250527641909/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD: EUROPE
INDUSTRY KEYWORD: AGRICULTURE NATURAL RESOURCES
SOURCE: Research and Markets
Copyright Business Wire 2025.
PUB: 05/27/2025 07:36 AM/DISC: 05/27/2025 07:35 AM
http://www.businesswire.com/news/home/20250527641909/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
The OG of 360 cameras returns –meet the Ricoh Theta A1
When you buy through links on our articles, Future and its syndication partners may earn a commission. Ricoh's new Theta A1 announcement promotes ruggedness, connectivity and speed in the field. It looks a lot like the brand, with over a decade's heritage in 360, is making a play against the action camera brands Insta360 and GoPro that are topping the best 360 cameras guide at the moment! The new Theta A1 was rumored recently, with discussion of a new battery being a key part of the leaks. A long-lasting replaceable 1,485 mAh battery is now a highlight of the official announcement, as is an optimized video codec that will further improve battery performance. UPDATE: We now know the price of the camea will be €799 (approximately £675 or $912, though US pricing will depend on tariffs at the time). The time in question will not be until September this year. "We're meeting the expectations of field professionals: robustness, speed, and integration," said Thomas Servan, managing director of Ricoh Futures EMEA. "It embodies our vision of useful, connected technology that aligns with the operational needs of our clients.' It is interesting that Ricoh seems to pitch the camera more toward professional customers, even though we've seen so much growth in the 'action camera' end of 360 cameras. Oddly, though, the needs seem to coincide: "rugged, waterproof, dustproof and extreme temperature-resistant casing" says the press release! The camera's spec sheet promises 60MP (11,008 x 5504) stills and has some interesting video formats, up to 8K (but at a maximum of 10fps) but also including 5.7K and 4K. There is even a 2fps option for the 8K, at a choice of 8, 16 or 24Mbps data rates – a lot of potential flexibility for any professional concerned with managing the data as much as quality. There is also the option of 2K or 4K live streaming. The Ricoh Theta A1 now sits in the company's lineup alongside the Theta Z1, which offers the highest resolution for precision scanning, and the Theta X with its integrated screen for versatility. That screen, by the way, makes it a more obvious contender for the consumer space than this business-like piece of kit. You will notice that the Theta SC2 no longer appears in what Ricoh calls its "newly restructured 360° camera lineup, focused squarely on professional use cases." All models, including the new Theta A1, are based on Theta Twin architecture, so compatibility with other Ricoh systems should be straightforward. The APIs and SDKs for this system have been public since 2013, and the Ricoh360 application will work with this camera as well as the others. Image 1 of 4 Gallery of sample images supplied by Ricoh – use the arrows to click through Image 2 of 4 Image 3 of 4 Image 4 of 4 The device is approximately 225g, IP64 dust and waterproof, and 142mm high (5.9 inches). The 7-element lenses are f/2.4 and the nearest focusing distance is 40cm. Each 1/2-inch sensor is approximately 48MP though, of course, because of the shape some of this data is lost, hence the 60MP files. Files are saved to the 27.5GB internal storage. As noted, the pricing information for Europe is set at €799 and the date is no more precise than "set for September" – we'll keep you posted. Check our guide to the best action cameras to get an idea what kind of thing a more rugged camera is expected to face. If you're interested in 360, don't just check the best 360 camera guide – we also have an Insta360 X4 vs X5 comparison. And have you heard the latest DJI Osmo 360 rumor?
Medscape
2 hours ago
- Medscape
Pegcetacoplan Maintains Kidney Benefits at 52 Weeks
Pegcetacoplan, a targeted C3/C3b inhibitor, shows sustained, robust effects on key markers of kidney disease in patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), according to 52-week results from the VALIANT trial. The 26-week results, which were presented last October at Kidney Week 2024, showed a highly significant difference in change in proteinuria from baseline, as measured by the urine protein-to-creatinine ratio (uPCR); the reduction was 67.2% with pegcetacoplan vs 2.9% with placebo ( P < .0001). The current findings showed that not only were these benefits sustained in patients who remained on pegcetacoplan, patients who switched from placebo to pegcetacoplan also experienced reductions of similar magnitude, said Fadi Fakhouri, MD, of Lausanne University Hospital and the University of Lausanne, Switzerland. Fakhouri presented the 1-year results at the 62nd European Renal Association (ERA) Congress 2025. VALIANT Open-Label Period The phase 3 VALIANT trial involved 124 patients with native or post-transplant recurrent C3 glomerulopathy or primary IC-MPGN who were randomly assigned to treatment two times a week with either subcutaneous pegcetacoplan 1080 mg, or weight-based doses for adolescents weighing ≤50 kg (n = 63); or to placebo (n = 61). In the subsequent 26-week open-label period, the placebo group crossed over and all patients received pegcetacoplan. Overall, 59 (93.7%) people in the pegcetacoplan group and 55 (90.2%) in the placebo group completed the study treatment and 52-week assessment. At week 52, patients in the original pegcetacoplan group maintained the significant proteinuria reduction that was observed at week 26, with a mean urine protein-to-creatinine ratio (UPCR) change at week 26 of –67.2% and at week 52 of –68.3%. Patients in the placebo group, who experienced a +3.2% change in uPCR at week 26, experienced a reduction of –51.3% at week 52 after being switched to pegcetacoplan. In addition, eGFR levels in the pegcetacoplan group dropped slightly from -1.2 mL/min/1.73 m2 at week 26 to -3.7 mL/min/1.73 m2 at week 52; in the placebo-to-pegcetacoplan group, the corresponding changes were -7.9 mL/min/1.73 m2 at week 26 and -4.7 mL/min/1.73 m2 at week 52. In terms of safety, pegcetacoplan remained well-tolerated in the second 26 weeks, and treatment-emergent adverse events (TEAEs) were similar between the two arms during the open-label period (pegcetacoplan-to-pegcetacoplan, 77%; placebo-to-pegcetacoplan, 73.7%). Overall, infusion-related TEAEs decreased from the randomized to open-label period in the pegcetacoplan-to-pegcetacoplan group (33.3% vs 9.8%, respectively), suggesting an improvement in tolerability over time. Adherence was high, at 97.6% of patients having an adherence of ≥90% to ≤100%, overall. Infections included two cases of pneumococcal pneumonia (including one that was serious) occurring during the open-label period, and there was one case each of streptococcal pharyngitis and urinary tract infection caused by Escherichia . No patient deaths or allograft losses were reported. 'The open-label period results confirm pegcetacoplan's significant effect on kidney function,' Fakhouri said. 'Patients in the placebo arm experienced a decline in eGFR during the randomized controlled period, but a stabilization after switching to pegcetacoplan, comparable to randomized controlled period results in the pegcetacoplan group,' he added. Patients With Baseline Nephrotic Range Proteinuria The results of subanalyses looking at several other trial outcomes were also presented at the meeting. These included an analysis of patients with nephrotic range proteinuria at baseline, who are at a notably high risk of rapid disease progression to kidney failure. At baseline, 24 patients in the pegcetacoplan arm (38.1%) and 16 in the placebo arm (26.2%) had nephrotic range proteinuria, defined as a uPCR ratio ≥3 g/g. At the end of the initial 26-week period, among patients with nephrotic range proteinuria, those treated with pegcetacoplan had a relative reduction of proteinuria of 72.1% compared with placebo ( P < .0001). Patients Treated With Immunosuppressive Therapies A second subanalysis evaluated outcomes among 48 (76%) participants in the pegcetacoplan group and 42 (69%) in the placebo group who were receiving concomitant immunosuppressive therapy at baseline. Patients were permitted to continue the immunosuppressants provided that the doses had remained stable during the preceding 12-week period and throughout the trial. The outcomes between the two groups were similar: Immunosuppressant-treated patients who received pegcetacoplan had a relative reduction of 70% in proteinuria vs placebo ( P < .0001), and among patients who did not receive immunosuppressants, the relative reduction was 64.5% compared to placebo ( P = .0005). At week 26, 62.5% (30/48) of immunosuppressant‐treated patients receiving pegcetacoplan achieved a ≥50% reduction in proteinuria from baseline vs 4.8% (2/42) on placebo ( P < .0001). Among those not on immunosuppressants, 53.3% (8/15) of the pegcetacoplan group met the same endpoint compared with 5.3% (1/19) in the placebo arm ( P = .0087). 'Reassuringly, proteinuria was reduced in both groups, and the immunosuppressed group had a highly statistically significant reduction,' said David Kavanagh, MD, of the National Renal Complement Therapeutics Centre, Newcastle University, Newcastle upon Tyne, United Kingdom, who presented this subanalysis. Other outcomes, including stabilization of eGFR, were also similar to the overall reductions, including those patients not on immunosuppressants. Importantly, rates of TEAEs were also comparable between the immunosuppressed and non-immunosuppressed patients. 'If you can reduce your proteinuria by at least 50%, you're going to have an outcome that can reduce the risk of kidney failure,' Kavanagh concluded. The studies were sponsored by Apellis. Fakhouri reported relationships with Apellis, Sobi, Novartis, Roche, Alexion Pharmaceuticals, and AstraZeneca. Kavanagh reported relationships with Idorsia, Novartis, Chemocentryx, Alexion Pharmaceuticals, Samsung, Sobi, Gyroscope Therapeutics, Purespring, and Apellis.
Yahoo
2 hours ago
- Yahoo
Deutsche Bank Considers Stablecoin or Joining Industry-Led Initiative, Exec Says
Deutsche Bank is studying stablecoins and tokenized deposits as part of its growing digital assets strategy, joining other major banks exploring blockchain infrastructure for payments and settlement. The bank is considering whether to issue its own stablecoin or join a broader industry initiative, Bloomberg reported, citing Sabih Behzad, Deutsche Bank's head of digital assets and currencies transformation. It's also weighing the development of a tokenized deposit system aimed at making payments more efficient, according to the report. Major banks in the U.S. are currently weighing the launch of a joint stablecoin in a bid to fend off competition from the cryptocurrency space. These reportedly include heavyweights like JPMorgan Chase (JPM), Bank of America (BAC), Citigroup (C) and Wells Fargo (WFC). Regulatory clarity in the European Union and pending stablecoin legislation in the U.S. have helped accelerate stablecoin adoption. Behzad said banks have options that range from acting as reserve managers to launching their own digital tokens. Deutsche Bank has said in a research report that stablecoins are on the verge of mainstream adoption as crypto legislation advances under the Donald Trump administration. Germany's largest lender has, meanwhile, invested in cross-border payments firm Partior and joined Project Agorá, a central bank-backed initiative focused on wholesale tokenized payments. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
